Hoffmann-La Roche Inc.

Omeros Corporation

Affitech Research as

Peregrine Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ag

Anita Kavlie

Christian Klein

Joerg Thomas Regula

Ulrich Brinkmann

Werner Scheuer

Remko Griep

Klaus Kaluza

Sergej Kiprijanov

Thomas Dudler

Wayne Richard Gombotz

Clark E Tedford

James Brian Parent

Herald Reiersen

Urs Beat Hagemann

Wolfgang Schaefer

Sabine Imhof-Jung

Hubert Kettenberger

Monika Baehner

Markus Thomas

Guy Georges

Stefan Seeber

Juergen Michael Schanzer

Kyle Schlunegger

Wayne R Gombotz

Remko Albert Griep

Urs B Hagemann

Kay-Gunnar Stubenrauch

Sergej Michailovic Kiprijanov

Joerg Thomas

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Compositions for inhibiting MASP-2 dependent complement activation

The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific anti-VEGF/anti-ANG-2 antibodies

Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.

Anti-VEGF antibody compositions and methods

The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Antibodies

The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises:

Antibodies against human angiopoietin 2

The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2).

The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies

Isolated antibodies which bind to CXC chemokine receptor 4

Growing community of inventors

Oslo, Norway

Anita Kavlie